Open AccessPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Author(s) -
Joaquim Bellmunt,
Ronald de Wit,
David J. Vaughn,
Yves Fradet,
JaeLyun Lee,
Lawrence Fong,
Nicholas J. Vogelzang,
Miguel Ángel Climent,
Daniel P. Petrylak,
Toni K. Choueiri,
Andrea Necchi,
Winald R. Gerritsen,
Howard Gurney,
David I. Quinn,
Stéphane Culine,
Cora N. Sternberg,
Yabing Mai,
Christian Poehlein,
Rodolfo F. Perini,
Dean F. Bajorin
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1613683
Subject(s) - medicine , pembrolizumab , hazard ratio , docetaxel , chemotherapy , oncology , population , gastroenterology , urology , cancer , confidence interval , surgery , immunotherapy , environmental health
Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom